Læknablaðið - 01.12.1962, Blaðsíða 59

IMETHYLDOPAI
INDICATED IN ALL DEGREES OF ESSENTIAL HYPERTENSION
Aldomet is a new and unique drug possessing significant features not
shared by any currently known antihypertensive agent.
is demonstrably effective in approximately 76% of
patients with cardiovascular hypertension.
confers “round-the-clock” protection; prevents
morning hypotension without sacrifice of afternoon blood
pressure control.
action is of short duration; a prompt return to pre-
treatment blo'od pressure levels, without overshoot,
follows withdrawal.
reduces both supine and standing blood pressure.
Supplied: Aldomet (methyldopa) in 250 mg. yellow, film-coated tablets; in bottles of
30, 100 and 500 tablets.
Before prescribmg or initiating therapy with Aldomet, pnysicians should see data describing dosaj-.e, ad-
ministration, and precautions, in package circular or available on reauest.
& M6RCK SHRRP B DOHRie IDieRnðTIODHL
Division of Merck & Co., Inc., 100 Church Street, New York 7, N. Y., U. S. A.